Ulhas M Nadgir, M.D.
Investigator
Ulhas M. Nadgir, MD is a board-certified pediatric endocrinologist with over two decades of experience in the diagnosis and management of endocrine disorders in children and adolescents. He currently practices with Sutter Medical Group and has held long-standing roles at leading endocrinology centers. Dr. Nadgir completed his pediatric endocrinology fellowship at Children’s Hospital of Buffalo and pediatric residencies in both the United States and India.
His clinical expertise includes growth hormone deficiency, diabetes, and complex pediatric endocrine conditions. Dr. Nadgir has contributed extensively to clinical research, serving as a principal investigator and sub-investigator on numerous national and multicenter trials, and has presented at major endocrinology and pediatric conferences.
In addition to his clinical and research work, he is actively involved in teaching and mentoring medical trainees, reflecting his commitment to advancing pediatric endocrine care.
Research studies
- Research study
Growth Hormone Deficiency SkybriGHt
A US Non-interventional, Effectiveness and Safety Study of Patients Treated With SKYTROFA (SkybriGHt)
Clinical trials
- Clinical trial
Congenital Adrenal Hyperplasia in Pediatrics CRN04894-13
A Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Atumelnant Treatment in Pediatric Participants With Congenital Adrenal Hyperplasia Including a Long-Term Extension
Status: Coming Soon
- Clinical trial
Diabetes Type II Pediatric ACHIEVE-PEDS J2A-MC-GZGY
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes
Status: Coming Soon
- Clinical trial
Growth Hormone Deficiency (GHD) LUM-201-10 OraGrowth
A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Growth Hormone Deficiency (GHD)
Status: Open to Enrollment
- Clinical trial
Idiopathic Short Stature ASND0047 HighLiGHts
A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents With Growth Failure or Short Stature Due to Growth Hormone Sufficient Disorders - Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature
Status: Open to Enrollment
- Clinical trial
Prader-Willi Syndrome TEMPO
A Phase 3, Randomized, Double-Blind, Placebo-controlled, Efficacy and Safety Study of Pitolisant Followed by an Open-Label Extension in Patients with Prader-Willi Syndrome
Status: Open to Enrollment